Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients
暂无分享,去创建一个
D. Dieterich | L. Piroth | J. Hand | David Del Bello | F. Nagy | Rabea Khedemi | Julien Lécluse-Barth
[1] T. Asselah,et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.
[2] D. Samuel,et al. P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis , 2015 .
[3] T. Pilot‐Matias,et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.
[4] Brad J. Wood,et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.
[5] J. Rockstroh,et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.
[6] P. Thuluvath,et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.
[7] H. Dvory‐Sobol,et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis , 2015, Hepatology.
[8] D. Neau,et al. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[10] D. Dieterich,et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] K. Mounzer,et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.
[12] Riina Salupere,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.
[13] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[14] R. Marinho,et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.
[15] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[16] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[17] Eoin Coakley,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[18] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[19] C. Stedman,et al. O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE , 2014 .
[20] Richard A. Stanton,et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors , 2014, Infection and Drug Resistance.
[21] S. Khoo,et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection , 2014, Current opinion in infectious diseases.
[22] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[23] R. Bertz,et al. Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir , 2013, Antiviral therapy.
[24] H. Mo,et al. Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 , 2013, Antimicrobial Agents and Chemotherapy.
[25] V. Soriano,et al. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.
[26] J. Mallolas,et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.
[27] Richard D Moore,et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.
[28] Giorgio Palù,et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.
[29] F. Carrat,et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.
[30] J. Montaner,et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.
[31] R. Chung,et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[33] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[34] M. Saag. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 , 2016 .
[35] Stefan Zeuzem,et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.